Navigation Links
VaxGen Provides Financial Update Following the Filing of Its 10-Q for Second Quarter With SEC; Results Include $8.5 Million Charge in Respect of Manufacturing Plant Asset Impairment
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided a financial and operational update since the filing of its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 14, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

VaxGen had approximately $59 million in cash and equivalents and investment securities as of June 30th, 2008, or $29 million net of the Company's $30 million of outstanding convertible debt. VaxGen reported a net loss for the second quarter of $10.4 million, reflecting a non-cash asset impairment charge of $8.5 million associated with the carrying value of the Company's manufacturing and laboratory assets. VaxGen's management and board determined to take this charge in light of an aborted transaction to sell the facility and associated equipment, and reflecting the length of time that the facility has been marketed without success.

James P. Panek, VaxGen's President and CEO, commented "While we have taken several important steps to preserve capital, we are obviously disappointed that the anticipated sale of the manufacturing plant and equipment fell through, having completed diligence and agreed to terms, for reasons entirely unrelated to VaxGen or the plant. In light of this, however, our expectations going forward need to reflect the difficulty we have experienced selling this asset. The encumbrance of the facility lease represents our single largest remaining financial liability."

Since the end of the second quarter, the Company has spent $18.3 million repurchasing $22 million in face value of its convertible debt, and received repayment of $6.3 million from Raven biotechnologies in respect of the bridge loan and accrued interest. As a result, VaxGen had approximately $46.5 million in cash and equivalents and investment securities as of July 31st, 2008, or $38.5 million net of the Company's $8 million of outstanding convertible debt.

On August 25, 2008, VaxGen received a $1 million milestone payment from Emergent BioSolutions, Inc., the purchaser of the Company's recombinant anthrax vaccine development program and associated assets, related to the generation of non-clinical data demonstrating the immunopotency and improved stability of the vaccine candidate.

During the second and third quarters, VaxGen further reduced its staff and operating expenses to preserve capital as it seeks to identify a strategic transaction which can deliver shareholder value. As a result of these cost cutting efforts, VaxGen will terminate Piers Whitehead, Vice President of Corporate and Business Development as of August 31 2008.

"With our new Strategic Transaction Committee of the Board fully engaged, and given the status of the transaction process, and our business, the Company and Piers can now part ways," said James P. Panek. "Piers has made innumerable contributions to VaxGen since joining VaxGen in 2002. His strategic thinking, negotiating skills and breadth of experience have been of tremendous value to the Company. He will be missed."

VaxGen expects its average monthly cash burn to be approximately $750,000, excluding unusual items. Management considers "cash burn" to be a non-GAAP financial measure. A reconciliation to GAAP is not provided since we are unable to predict the occurrence of unusual items which could be material to the company's results of operations.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. The facility is contained within leased premises. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the VaxGen's anticipated cash expenditures and its potential sale of assets and assignment of lease. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. VaxGen and Raven biotechnologies Announce Signing of Definitive Merger Agreement
2. VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven
3. VaxGen Restructures Following Termination of Proposed Merger
4. Study provides hope that some transplant patients could live free of antirejection drugs
5. Study provides hope that some transplant patients could live free of anti-rejection drugs
6. USAID Provides Additional Wildfire Assistance to Greece
7. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
8. New knock-out gene model provides molecular clues to breast cancer
9. PreMD Provides Update on 510(k) Application for PREVU(x) POC
10. SIV infection of natural hosts provides new insights into HIV disease complexity
11. Microarray provides 3 genomic guides to breast cancer treatment decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... FALLS, Wis (PRWEB) , ... February 22, 2017 ... ... in a category by itself - the Vector™ Series Multi-Cook Oven offers up ... individual oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. ...
(Date:2/21/2017)... ... February 21, 2017 , ... Tripp ... new hospital-grade power extension cords that meet the most current standards. , The ... edition of the National Fire Protection Association (NFPA) 101 – Life Safety Code ...
(Date:2/21/2017)... ... February 21, 2017 , ... Ray Insurance Agencies, a Dallas area firm providing ... is embarking on a six month charity event aimed at raising local support and ... is one of the deadliest diseases in America; more than 7.5 million people die ...
(Date:2/21/2017)... ... 2017 , ... Atlanta-based Jvion, the leading cognitive clinical science ... practice. Predixion, which raised $42M+ to date, received $20M in its third ... Ventures, and Software AG , will bring top industry talent and an impressive ...
(Date:2/21/2017)... ... , ... Along with Valentine’s Day, February marks American Heart Month, a great ... to a lifetime of heart health. In addition, it is a time to ... Athletic Trainers’ Society of New Jersey (ATSNJ) is urging sports programs to prepare comprehensive ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... BEACH, Va. , Feb. 21, 2017  Global ... now covers Dermacell ® for breast ... foot ulcers. Dermacell is an advanced acellular dermal matrix ... Technologies, Inc. (NASDAQ: NVDQ ) ... the four major commercial health-care payers to review the ...
(Date:2/21/2017)... 2017   BeyondSpring Pharmaceuticals , a clinical ... innovative immuno-oncology cancer therapies, today announced that the ... Phase 2 trial of BeyondSpring,s innovative lead asset, ... cell lung cancer (NSCLC) with Docetaxel has been ... Clinical Immuno-Oncology Symposium in Orlando, Fla. ...
(Date:2/21/2017)... , Feb. 21, 2017 EMS Find, ... and web based platforms with focus on e-commerce, ... the signing of a worldwide, on-revocable and renewable ... full-service medical transportation company serving healthcare organizations and ... . EpicMD,s platform eliminates the ...
Breaking Medicine Technology: